Answers are grounded in this paper and cite their sources.
Background Monocarboxylate transporter 1 (MCT1), encoded by SLC16A1 , mediates the transport of monocarboxylate substrates across the plasma membrane. MCT1 deficiency was first described as a rare inherited metabolic disorder characterized by impaired lactate transport and subsequently as a disorder of ketone body trafficking, resulting in a broad clinical phenotype, while regulatory gain-of-function variants in SLC16A1 are an established cause of exercise-induced hyperinsulinemic hypoglycemia. We performed a systematic literature review to summarize the clinical, biochemical, genetic, and functional features reported in individuals with SLC16A1 variants. Results Reported individuals exhibited considerable phenotypic heterogeneity. Two major clinical presentation patterns were identified in group A ( n = 26). The first comprised exercise-induced hyperlactic acidemia with or without rhabdomyolysis, and the second was characterized by recurrent episodes of ketoacidosis, typically presenting during infancy or early childhood. Functional studies demonstrated impaired MCT1 expression or monocarboxylate transport for both groups. Group B ( n = 54) included regulatory promoter variants associated with exercise-induced hyperinsulinemic hypoglycemia. In addition, group C was composed of population studies identified several common SLC16A1 variants without associated pathology ( n = 714). Conclusions SLC16A1 variants are linked to clinical heterogeneity with manifestations that extend isolated disturbances of lactate or ketone metabolism. This review provides a comprehensive synthesis of the currently available evidence and identifies gaps that warrant further investigation to better define the pathophysiology of this inborn error of metabolism, a probably often missed diagnosis.
No takes yet. Share an insight, caveat, or question.
Silva et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: